Primary Prevention

Healio and Cardiology Today have compiled a list of the most-popular news on heart disease prevention published in 2019.

Strategies with enhanced motivational interviewing did not improve physical activity or weight loss in patients at high CVD risk compared with standard community-based programs, nor were they cost-effective, according to results from the MOVE IT trial.

The Endocrinologic and Metabolic Diseases Advisory Committee of the FDA voted 16-0 in favor of the safety and efficacy of icosapent ethyl, based on available data, to support its approval for an indication to reduce risk for CV events.

Individuals living in less walkable urban areas have a higher 10-year risk for CVD than those living in highly walkable settings, according to findings published in the Journal of the American Heart Association.

The frequency of drinking is a more significant risk factor for new-onset atrial fibrillation than amount of alcohol consumed, according to a recent study published in EP Europace.

CHICAGO — In this video exclusive, Elizabeth McNally, MD, PhD, cardiologist and director of the Center for Genetic Medicine at Northwestern University, discusses implications of straight-to-consumer genetic testing, the subject of her presentation at the Cardiometabolic Health Congress.

Among a U.S. population of socioeconomically disadvantaged adults, a polypill-based strategy was associated with greater reductions in systolic BP and LDL compared with the usual care, according to findings published in The New England Journal of Medicine.

Taking aspirin for primary prevention of cardiovascular disease does not benefit older adults, according to findings from the ASPREE trial presented at the European Society of Cardiology Congress.

PARIS — Implantable cardioverter defibrillators were underutilized for primary prevention in patients with HF with reduced ejection fraction despite their ability to reduce short- and long-term all-cause mortality, according to a prospective propensity-score matched analysis presented at the European Society of Cardiology Congress.

PARIS — The European Society of Cardiology released five new guidelines, which introduce fresh recommendations such as an LDL goal of less than 55 mg/dL in patients at very high risk for CVD and the use of SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes requiring CVD prevention.